Announcements Trials

Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Skin Diseases 2 Neoplasms by Site 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Uterine Cervical Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Prostatic Neoplasms 1 Precancerous Conditions 1 Neoplasm Metastasis 1 Kidney Neoplasms 1 Hematologic Diseases 1 Genital Neoplasms, Female 1 Genital Diseases, Female 1 Genital Diseases 1 Female Urogenital Diseases and Pregnancy Complications 1 Communicable Diseases 1 Breast Neoplasms 1 Breast Diseases 1 Autoimmune Diseases 1

Interventions

pembrolizumab 7 Ipilimumab 7 Nivolumab 5 Melphalan 5 Dacarbazine 3 tebentafusp 2 sotrastaurin 2 binimetinib 2 Pemetrexed 2 Crizotinib 2 ADI PEG20 2 utomilumab 1 trametinib 1 tocilizumab 1 siremadlin 1 ruxolitinib 1 relatlimab 1 obinutuzumab 1 fludarabine phosphate 1 fludarabine 1 cemiplimab 1 avelumab 1 Watchful Waiting 1 Toll-Like Receptor 1 1 Standard of Care 1 Solutions 1 Rose Bengal 1 Protein Kinase C 1 Polyethylene Glycols 1 Opdualag 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Uveal Melanoma × Watchful Waiting × Clear all

NCT07338968 2026-01-14

CoMpass

Aura Biosciences

Not yet recruiting

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡